Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT02846727

Using Fluorescence Angiography to Detect Occult Shock

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Yale University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine if fluorescence angiography can detect occult shock (hypoperfusion).

Detailed description

Hypoperfusion may be multifactorial, due to hemorrhage, shock or other disease processes resulting in either capillary leak into the interstitium or profound vasodilatation. Currently, diagnosis of hypoperfusion depends on indirect markers of perfusion such as lactate, blood pressure, creatinine, urine output, and mental status. These are all late signs of hypoperfusion as they are precursors to impending system failure. In this study, the focus will be on one of the most common causes of hypoperfusion in the surgical population; sepsis and septic shock.

Conditions

Interventions

TypeNameDescription
DEVICEskin perfusion imageUpon enrollment following written, informed consent, the patient will receive an injection of 7.5 mg of Indocyanine Green (ICG) intravenously (Dilute 25 mg of Indocyanine Green (ICG) with 10 cc of solvent to achieve a 2.5 mg/cc concentration.) Following injection, Novadaq's LUNA™ fluorescence angiography system will be utilized to map a standard skin perfusion image (SPI) over the upper extremities and anterior chest wall.

Timeline

Start date
2016-08-01
Primary completion
2018-08-01
Completion
2018-09-01
First posted
2016-07-27
Last updated
2018-01-11

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02846727. Inclusion in this directory is not an endorsement.